How should a 3‑month postpartum lactating mother with focal segmental glomerulosclerosis (FSGS) who relapsed while on steroids be managed?

Management of Relapsed FSGS in a Lactating Postpartum Mother

For this 3-month postpartum lactating mother with FSGS who has relapsed while on steroids, you should immediately initiate a glucocorticoid-sparing agent—specifically a calcineurin inhibitor (tacrolimus or cyclosporine)—while continuing low-dose steroids for 2 weeks after starting the CNI, and strongly advise against breastfeeding during immunosuppressive therapy.

Immediate Treatment Approach

First-Line Therapy: Calcineurin Inhibitors

Add a calcineurin inhibitor as your primary steroid-sparing agent 1. The evidence strongly supports CNIs for steroid-dependent or frequently relapsing FSGS:

• Tacrolimus: Start at 0.1-0.2 mg/kg/day divided in two doses
• Cyclosporine: Start at 2-3 mg/kg/day, gradually increase to maximum 4 mg/kg/day based on levels 2

Target levels:

• Cyclosporine: C0 = 125-175 ng/mL, C2 <500 ng/mL 2
• Tacrolimus: Trough 5-10 ng/mL

Continue glucocorticoids for 2 weeks after initiating the CNI, then taper steroids to the minimum effective dose 1.

Alternative Steroid-Sparing Options

If CNIs are contraindicated or not tolerated, consider these alternatives in order of preference 1:

1. Rituximab: 1-4 doses (though insufficient data for specific dosing recommendations) - particularly effective for steroid-dependent disease 3
2. Mycophenolate mofetil: Can be combined with CNIs for complicated cases 1, 4
3. Cyclophosphamide: 2 mg/kg/day for 8-12 weeks (maximum cumulative dose 168 mg/kg) - though less preferred in reproductive-age women 5

Critical Lactation Consideration

Breastfeeding must be discontinued during immunosuppressive therapy. All immunosuppressive agents (steroids at immunosuppressive doses, CNIs, rituximab, cyclophosphamide, mycophenolate) are contraindicated during lactation due to infant exposure risks. This is a non-negotiable safety issue that requires frank discussion with the patient about risk-benefit analysis.

Treatment Duration and Monitoring

• CNI therapy: Maintain for 12-24 months minimum after achieving remission 2
• Taper strategy: Reduce CNI by 0.5 mg/kg/month to minimum effective dose after complete remission 2
• Monitoring frequency:
  • Weekly initially for proteinuria (urine protein-creatinine ratio)
  • Monthly CNI levels and renal function
  • Monitor for CNI nephrotoxicity (GFR decline >20% warrants dose adjustment) 2

Defining Treatment Response

Complete remission: Proteinuria <0.3 g/day with stable renal function Partial remission: ≥50% reduction in proteinuria to <3.5 g/day with stable renal function

If no response (minimum 50% reduction in proteinuria) after 6 months of CNI therapy, consider adding or switching to alternative agents 2.

Supportive Management

While initiating immunosuppression:

• ACE inhibitor or ARB: Essential for proteinuria reduction and renoprotection 2, 6
• Statin therapy: For hyperlipidemia management 2
• Diuretics: For edema control as needed
• Target blood pressure: <120/80 mmHg 7

Common Pitfalls to Avoid

1. Inadequate CNI dosing: Many relapses occur from subtherapeutic CNI levels—monitor trough levels religiously
2. Premature steroid discontinuation: Continue steroids for 2 weeks after starting CNI to prevent breakthrough relapse 1
3. Stopping therapy too early: CNIs require 6-12 months to achieve maximum benefit 2
4. Allowing continued breastfeeding: This exposes the infant to immunosuppressive drugs with unknown long-term consequences

Special Considerations for Postpartum Status

This patient's postpartum status requires additional attention:

• Screen for postpartum-related complications (preeclampsia sequelae, volume status)
• Ensure adequate contraception counseling—pregnancy should be avoided during active immunosuppression
• Plan for long-term follow-up given increased cardiovascular and kidney disease risk after pregnancy-related complications 7

When to Consider Kidney Biopsy

Repeat biopsy is indicated if 5:

• Failure to respond to CNI therapy after 6 months
• Unexplained decline in renal function while on CNI (to distinguish CNI toxicity from disease progression)
• Suspicion of secondary FSGS causes

The key to success is early, aggressive steroid-sparing therapy with CNIs while maintaining close monitoring for both treatment response and drug toxicity. Most patients with steroid-dependent FSGS will require long-term maintenance immunosuppression to prevent relapse 1.